Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Stock Forecast

Stock Price Forecast

The 7 analysts that cover Arcutis Biotherapeutics stock have a consensus rating of "Strong Buy" and an average price target of $31.86, which forecasts a 31.14% increase in the stock price over the next year. The lowest target is $19 and the highest is $36.

Price Target: $31.86 (+31.14%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$19	$31.86	$35	$36
Change	-21.79%	+31.14%	+44.06%	+48.18%

Analyst Ratings

The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	4	4	5	5
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	8	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Uy Ear Mizuho	Mizuho	Buy Maintains $37 → $35	Buy	Maintains	$37 → $35	+44.06%	Mar 2, 2026
Seamus Fernandez Guggenheim	Guggenheim	Strong Buy Maintains $34 → $35	Strong Buy	Maintains	$34 → $35	+44.06%	Feb 27, 2026
Tyler Van Buren TD Cowen	TD Cowen	Strong Buy Maintains $30 → $35	Strong Buy	Maintains	$30 → $35	+44.06%	Feb 26, 2026
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $30 → $34	Strong Buy	Maintains	$30 → $34	+39.95%	Feb 26, 2026
Serge Belanger Needham	Needham	Strong Buy Maintains $31 → $36	Strong Buy	Maintains	$31 → $36	+48.18%	Feb 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

505.67M

Increased by 34.46%

from 376.07M

Revenue Next Year

656.20M

Increased by 29.77%

from 505.67M

EPS This Year

0.32

from -0.13

EPS Next Year

1.20

Increased by 274.91%

from 0.32

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	3.69M	59.61M	196.54M	376.07M	505.67M	656.20M
Revenue Growth	-	-	1,517.09%	229.74%	91.34%	34.46%	29.77%
EPS	-4.18	-5.66	-3.78	-1.16	-0.13	0.32	1.20
EPS Growth	-	-	-	-	-	-	274.91%
Forward PE	-	-	-	-	-	75.90	20.24
No. Analysts	-	-	-	-	-	10	10

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	538.3M	737.2M
Avg	505.7M	656.2M
Low	478.2M	611.3M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	43.1%	45.8%
Avg	34.5%	29.8%
Low	27.2%	20.9%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	0.56	1.69
Avg	0.32	1.20
Low	0.08	0.70

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	428.1%
Avg	-	274.9%
Low	-	117.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.